Publications
324 results found
Mullish BH, McDonald JA, Kao DH, et al., 2017, Understanding the Mechanisms of Efficacy of Fecal Microbiota Transplantation in the Treatment of Clostridium Difficile Infection: The Potential Role of Bilemetabolising Enzymes, Publisher: Elsevier BV, Pages: S47-S47, ISSN: 0016-5085
Dhar A, Mullish BH, Thursz MR, 2017, Grand round: anticoagulation in chronic liver disease, Journal of Hepatology, Vol: 66, Pages: 1313-1326, ISSN: 1600-0641
In this Grand Round, we first present a case of a man with decompensated liver disease who subsequently developed a fatal pulmonary embolism, having not been prescribed prophylactic anticoagulation to prevent venous thromboembolic disease. We go on to discuss the burden of thrombotic disease in those with chronic liver disease, before a more detailed discussion regarding the current evidence, safety data, and clinical dilemmas regarding the use of anticoagulation in patients with chronic liver disease, as well as discussing potential future directions within this field.
Glen J, Floros L, Day C, et al., 2016, GUIDELINES Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance, BMJ-BRITISH MEDICAL JOURNAL, Vol: 354, ISSN: 0959-535X
- Author Web Link
- Cite
- Citations: 117
, 2016, Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline [NG49], Non-alcoholic fatty liver disease (NAFLD): assessment and management, Publisher: NICE, NICE Guideline NG49
Quraishi MN, Segal J, Mullish B, et al., 2016, OC-040 National Survey of Practice of Faecal Microbiota Transplantation for Clostridium Difficile Infection in the United Kingdom, Publisher: BMJ, Pages: A23.2-A24, ISSN: 0017-5749
Mullish BH, McDonald JAK, Pechlivanis A, et al., 2016, PWE-094 Understanding The Efficacy of Faecal Microbiota Transplantation in Clostridium Difficile Infection: Re-Establishment of Gut Microbiota with The Ability to Degrade Bile?, Publisher: BMJ, Pages: A184.2-A184, ISSN: 0017-5749
Jones A, Mullish BH, Williams HRT, et al., 2016, Improvements in Clostridium difficile infection in England and comparative epidemiology with the US, 33rd International Society for Quality in Health Care Conference 2016, Publisher: Oxford University Press (OUP), ISSN: 1464-3677
Gratton J, Phetcharaburanin J, Mullish BH, et al., 2016, An optimized sample handling strategy for metabolic profiling of human feces, Analytical Chemistry, Vol: 88, Pages: 4661-4668, ISSN: 0003-2700
Fecal metabolites are being increasingly studied to unravel the host-gut microbial metabolic interactions. However, there are currently no guidelines for fecal sample collection and storage based on a systematic evaluation of the effect of time, storage temperature, storage duration and sampling strategy. Here we derive an optimized protocol for fecal sample handling with the aim of maximizing metabolic stability and minimizing sample degradation. Samples obtained from five healthy individuals were analyzed to assess topographical homogeneity of feces, and to evaluate storage duration-, temperature- and freeze-thaw cycle-induced metabolic changes in crude stool and fecal water using a 1H NMR spectroscopy-based metabolic profiling approach. Inter-individual variation was much greater than that attributable to storage conditions. Individual stool samples were found to be heterogeneous and spot sampling resulted in a high degree of metabolic variation. Crude fecal samples were remarkably unstable over time and exhibited distinct metabolic profiles at different storage temperatures. Microbial fermentation was the dominant driver in time-related changes observed in fecal samples stored at room temperature and this fermentative process was reduced when stored at 4°C. Crude fecal samples frozen at -20°C manifested elevated amino acids and nicotinate and depleted short chain fatty acids compared to crude fecal control samples. The relative concentrations of branched-chain and aromatic amino acids significantly increased in the freeze-thawed crude fecal samples, suggesting a release of microbial intracellular contents. The metabolic profiles of fecal water samples were more stable compared to crude samples. Our recommendation is that intact fecal samples should be collected, kept at 4°C or on ice during transportation, and extracted ideally within 1 h of collection, or a maximum of 24 h. Fecal water samples should be extracted from a representative amount (~15 g)
Mannan I, Cheung V, Grout C, et al., 2016, Psychiatry, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 313-313
Mannan I, Cheung V, Grout C, et al., 2016, Clinical sciences, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 95-95
Mannan I, Cheung V, Grout C, et al., 2016, Geriatric medicine, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 169-169
Mannan I, Cheung V, Grout C, et al., 2016, Endocrinology, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 143-143
Mannan I, Cheung V, Grout C, et al., 2016, Nephrology, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 271-271
Mannan I, Cheung V, Grout C, et al., 2016, Neurology, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 237-237
Mannan I, Cheung V, Grout C, et al., 2016, Rheumatology, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 357-357
Mannan I, Cheung V, Grout C, et al., 2016, Gastroenterology, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 179-179
Mannan I, Cheung V, Grout C, et al., 2016, Clinical haematology and oncology, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 27-27
Mannan I, Cheung V, Grout C, et al., 2016, Cardiology, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 1-1
Mannan I, Cheung V, Grout C, et al., 2016, Ophthalmology, MRCP Part 1: 400 BOFs, Publisher: Jaypee Brothers Medical Publishers (P) Ltd., Pages: 303-303
Mannan I, Cheung V, Grout C, et al., 2015, MRCP Part 1: 400 BOFs, Publisher: JP Medical Ltd, ISBN: 978-1909836426
Topan R, James S, Mullish BH, et al., 2015, Weight loss in a man from West Africa. S. stercoralis hyperinfection., Gut, Vol: 64, Pages: 1846-1888
Mullish BH, Williams HRT, 2015, Obstacles to establishing an NHS faecal transplant programme., BMJ (Clinical research ed.), Vol: 351, ISSN: 0959-8138
- Open Access Link
- Cite
- Citations: 5
Pealing LM, Mullish BH, Smith PJ, et al., 2015, MRCP PACES Manual, Publisher: PasTest, ISBN: 978-1905635757
Mullish BH, Marchesi JR, Thursz MR, et al., 2015, Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infection., QJM, Vol: 108, Pages: 355-359
Faecal microbiome transplantation (FMT) has generated huge recent interest as it presents a potential solution to a significant clinical problem--the increasing incidence of Clostridium difficile infection (CDI). In the short term, however, there remain many practical questions regarding its use, including the optimal selection of donors, material preparation and the mechanics of delivery. In the longer term, enhanced understanding of the mechanisms of action of FMT may potentiate novel therapies, such as targeted manipulation of the microbiome in CDI and beyond.
Mullish BH, Kabir MS, Thursz MR, et al., 2015, Letter: depression and the use of anti‐depressants in patients with chronic liver disease or liver transplantation – authors’ reply, Alimentary Pharmacology & Therapeutics, Vol: 41, Pages: 914-915, ISSN: 0269-2813
Smith LJ, Quint JK, Brown JS, 2015, Respiratory Medicine, Publisher: JP Medical Ltd, ISBN: 9781907816727
Mullish BH, Fofaria RK, Smith BC, et al., 2014, Severe cholestatic jaundice after a single administration of ajmaline; a case report and review of the literature, BMC Gastroenterology, Vol: 14
Mullish BH, 2014, Case 25-2014: A man with ulcerative colitis and bloody diarrhea., The New England journal of medicine, Vol: 371, ISSN: 0028-4793
Mullish BH, Kabir MS, Thursz MR, et al., 2014, Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation, Alimentary Pharmacology & Therapeutics, Vol: 40, Pages: 880-892, ISSN: 0269-2813
<jats:title>Summary</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>The scale of depression in patients with chronic liver disease (<jats:styled-content style="fixed-case">CLD</jats:styled-content>) and those who have received orthotopic liver transplantation (<jats:styled-content style="fixed-case">OLT</jats:styled-content>) is poorly characterised. Clinicians are uncertain of how best to manage depression within these patients.</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>To review the literature evaluating both the prevalence and impact of depression in patients with <jats:styled-content style="fixed-case">CLD</jats:styled-content> and post‐<jats:styled-content style="fixed-case">OLT</jats:styled-content>, and to assess the safety and efficacy of antidepressant use within this context.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>A PubMed search using the phrases ‘chronic liver disease’, ‘cirrhosis’, ‘liver transplantation’, ‘depression’, ‘antidepressant’ and the names of specific causes of liver disease and individual antidepressants.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Over 30% of cirrhotic patients have depressive features, and they experience worse clinical outcomes than nondepressed cirrhotic patients. <jats:styled-content style="fixed-case">CLD</jats:styled-content> patients with chronic hepatitis C are particularly prone to depression, partly related to the use of interferon therapy. <jats:styled-content style="fixed-case">OLT</jats:styled-content> patients with depression have higher mortality rates than nondepressed patients; appro
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.